1. Show article details.

    Drugmaker Abbott says not pursuing an offer for St Jude Medical

    Reuters – 10:21 AM ET 08/27/2015

    - Drugmaker Abbott Laboratories , knocking down a report in the Financial Times, denied on Thursday that it was preparing a bid for medical device maker St Jude Medical Inc (STJ) . The FT, citing people familiar with the matter, reported that Abbott has been working with advisers for several weeks to line up financing for a $25 billion cash and stock bid for St. Paul, Minnesota-based St...

  2. Abbott Laboratories up 3% as it denies St. Jude acquisition talk

    MarketWatch – 9:38 AM ET 08/27/2015
  3. Show article details.

    Abbott says it's not pursuing $25 billion offer for St. Jude

    MarketWatch – 8:49 AM ET 08/27/2015

    Abbott Laboratories (ABT) has denied reports that it is pursuing a $25 billion bid to buy St. Jude traded sharply higher in premarket trade following a Financial Times report, citing anonymous sources. Jude's shares were up 5% in premarket trade, putting them on track to open around $73. Those of Abbott were up 3.2%.

  4. Abbott says it's not pursuing an offer for St. Jude

    MarketWatch – 8:40 AM ET 08/27/2015
  5. Abbott Labs' stock rallies 3.5% premarket after report of takeover interest in St. Jude Medical

    MarketWatch – 7:49 AM ET 08/27/2015
  6. Abbott Labs preparing $25 bln bid for St. Jude Medical: FT

    MarketWatch – 7:23 AM ET 08/27/2015
  7. Show article details.

    St. Jude Medical shares surge 13% on report Abbott Labs prepping $25 bln bid

    MarketWatch – 7:21 AM ET 08/27/2015

    Jude Medical Inc. shares surged 12% in premarket trade Thursday, after the Financial Times reported that Abbott Laboratories (ABT) is gearing up to make a $25 billion bid for the medical device maker, citing people familiar with the matter. The company is preparing an offer but has not yet put it forward, the paper said. Abbott Labs (ABT) shares were not yet active in premarket trading.

  8. Show article details.

    Drugmaker Abbott preparing bid for device maker St Jude - FT

    Reuters – 7:10 AM ET 08/27/2015

    Drugmaker Abbott Laboratories is preparing a bid for St Jude Medical Inc (STJ) that would value the medical device maker at about $25 billion, the Financial Times reported, citing people familiar with the matter. Abbott has been working with advisers for several weeks to line up financing for a cash and stock offer, the report said.

  9. Show article details.

    New Concussion Survey Reveals Majority of Adults are Unable to Recognize Common Concussion Symptoms

    PR Newswire – 9:00 AM ET 08/24/2015

    ABBOTT PARK, Ill., Aug. 24, 2015  With students heading back to school and the fall sports season approaching, surprising new data from Abbott's Concussion IQ Survey reveals that a large number of adults in the United States lack basic understanding about concussion signs and symptoms, risk and treatment.

  10. Show article details.

    Mylan, Perrigo Notch Wins in Their Takeover Fight

    DJ Business News – 8:45 AM ET 08/14/2015

    Rival generic-drug makers Mylan NV (MYL) and Perrigo Co. (PRGO) both chalked up wins this week in their hostile $36 billion takeover fight, which is heading into the homestretch. Mylan in April publicly bid for Perrigo (PRGO), saying a combination would create a strong competitor in the quickly consolidating pharmaceuticals sector. Perrigo (PRGO) has rejected the price as too low.

  11. Show article details.

    Shire Mounts $30.6 Billion Bid for Biotech

    DJ Business News – 8:15 AM ET 08/04/2015

    Shire PLC (SHPG) on Tuesday made public an unsolicited $30.6 billion takeover bid for rare-disease treatment maker Baxalta Inc. (BXLT), becoming the latest deal-hungry company refusing to take "no" for an answer amid the current deal boom. The proposed tie-up pushes unsolicited U.S. takeover bids to a multiyear high by value, as emboldened chief executives pursue reluctant suitors despite the risks and distractions that typically ensue with large public takeover battles.

  12. Show article details.

    Abbott Laboratories Acquisition

    DJ Business News – 11:22 AM ET 07/30/2015

    Abbott to Broaden Foundation in Structural Heart Therapies with Two Mitral Valve Transactions. -Acquisition of Tendyne Holdings, Inc. to Expand Abbott's Mitral Valve Therapies. -In Separate Transaction, Abbott Has Provided Capital and Secured an Option to Purchase Cephea Valve Technologies.

  13. Show article details.

    Abbott strikes deals with heart valve replacement companies

    Reuters – 11:12 AM ET 07/30/2015

    Abbott Laboratories (ABT) on Thursday said it would buy a small private company and has invested in another, with an option to buy, as it places bets on the future growth potential of minimally invasive systems to replace diseased heart valves.

  14. Show article details.

    BRIEF-Abbott announces two Mitral valve transactions

    Reuters – 11:05 AM ET 07/30/2015

    Abbott Laboratories (ABT). * Abbott says will acquire the equity of Tendyne that it does not already own for $225 million upfront. * To purchase Tendyne holdings inc for total transaction value of $250 million, plus potential future payments. * In a separate transaction, provided capital and secured option to purchase Cephea Valve Technologies; financial terms not disclosed.

  15. Show article details.

    Abbott to Broaden Foundation in Structural Heart Therapies with Two Mitral Valve Transactions

    PR Newswire – 11:00 AM ET 07/30/2015

    ABBOTT PARK, Ill., July 30, 2015 Abbott announced today that it has entered into an agreement to purchase Tendyne Holdings, Inc., a private medical device company focused on developing minimally invasive mitral valve replacement therapies. Tendyne's Bioprosthetic Mitral Valve System is an investigational device and not currently available for sale.

  16. Show article details.

    Abbott Partners with the 2015 BMW BERLIN-MARATHON to Celebrate the Power of Health

    PR Newswire – 10:53 AM ET 07/24/2015

    BERLIN, July 24, 2015 The organizers of the BMW BERLIN-MARATHON today proudly announced a new partnership with the global healthcare company Abbott , which became an Official Sponsor of the 2015 BMW BERLIN-MARATHON, one of six iconic races in the Abbott World Marathon Majors series.

  17. Show article details.

    Danone swaps Dumex China unit for deeper ties with domestic dairy giant

    Reuters – 12:56 AM ET 07/24/2015

    * Plans to sell Dumex business to part-owned Yashili. * Dumex sales had plunged after series of food scares. * French firm to raise 9.9 pct stake in dairy giant Mengniu. * Competition rising in China's $20 bln formula market. By Donny Kwok and Adam Jourdan.

  18. Show article details.

    Abbott Labs Profit Beats Expectations

    DJ Business News – 9:45 AM ET 07/22/2015

    Abbott Laboratories Inc. said its profit climbed 68% in the latest quarter on robust sales in its established pharmaceutical products segment and a gain on the sale of a portion of Mylan N.V. (MYL) stock. "We've achieved another quarter of strong sales growth led by our global diagnostics and branded generics businesses," said Chief Executive Miles White. Overall for the second quarter ended June 30, Abbott reported a profit of $784 million, or 52 cents a share, compared with $466 million,...

  19. Show article details.

    Abbott Labs Profit Beats Expectations

    DJ Business News – 9:35 AM ET 07/22/2015

    Abbott Laboratories Inc. said its profit climbed 68% in the latest quarter on robust sales in its established pharmaceutical products segment and a gain on the sale of a portion of Mylan N.V. stock. "We've achieved another quarter of strong sales growth led by our global diagnostics and branded generics businesses," said Chief Executive Miles White. Overall for the second quarter ended June 30, Abbott reported a profit of $784 million, or 52 cents a share, compared with $466 million,...

  20. Show article details.

    Abbott backs profit view on diagnostics, generics strength

    Reuters – 8:41 AM ET 07/22/2015

    * Diagnostics, generics expected to keep growing. * Growth expected to negate effect of strong dollar. * Q2 profit, revenue beat market estimates. * Sees FY adj EPS $2.10-$2.20 vs est $2.16. * Shares rise 2.6 percent to record high. By Vidya L Nathan.

Page:

Today's and Upcoming Events

  • Oct
    21

    ABT to announce Q3 earnings Before Market (Unconfirmed)

Past Events (last 90 days)

  • Jul
    22

    ABT Earnings Conference Call at 9:00 AM Listen

  • Jul
    13

    ABT ex-Dividend for $0.24 on 7/13/2015

    • Announce Date: 6/12/2015
    • Record Date: 7/15/2015
    • Pay Date: 8/15/2015
Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.